Rising air pollution owing to increase in amount of harmful gasses like Chlorofluorocarbons, Carbon

monoxide, Carbon dioxide, Nitrogen Oxide, Nitrogen dioxide and many more due to industrialization,
increase in amount of vehicles, and other CFCs emitting appliances has caused in an increase in the
number of respiratory diseases. Humans inhale theses toxic gasses and the result in damage in their air
sacs and lungs.

The increase in Respiratory problems has influenced the Therapeutic market of the respiratory disorders
positively. DelveInsight, a Healthcare consulting company, observed that degradation in air quality has
fuelled the market of air-borne disorders like Pneumonia, Acute respiratory distress syndrome (ARDS),
Bronchitis, and many more.

Acute respiratory distress syndrome (ARDS) is a severe form of lung condition characterized by excess
fluid in the air sacs of lungs. This decrease the amount of oxygen in the bloodstream which ultimately
causes failure of an organ. Not only air pollution but road accidents which result in damage in all the lobes
of the lungs can also lead to ARDS. Moreover, inflammation of pancreas, coupled with massive blood
transfusions, can lead to advanced respiratory problems.

DelveInsight estimates that total ARDS incident population in the 7MM is estimated to be growing at a
CAGR of 1.35% for the study period i.e. 2016-2027. Moreover, a higher acute respiratory distress
syndrome incidence in the United States with expected 605,175 cases in 2027. Furthermore, based on the
recent studies and data from registries show highest number of incident cases were assessed for ARDS
due to Pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary
risk factor for ARDS.

Acute respiratory distress syndrome treatment, as studied by DelveInsight, is mainly supportive, which
includes invasive mechanical ventilation with lung protective strategies. However, long-term intubation
may carry a high rate of complications, including ventilator-associated pneumonia, delirium and critical
illness myopathy and neuropathy. Noninvasive ventilation (NIV) and the application of continuous positive
airway pressure (CPAP) is contemplated in mild ARDS, although its use in acute hypoxemic respiratory
failure remains controversial and the choice of the interface device is still debated.

Overall, the dynamics of ARDS market is anticipated to change during the forecast period, owing to the
expected launch of emerging therapies during the forecast period of 2019-2028. Key players in the Acute
respiratory distress syndrome market like Faron Pharmaceuticals, Implicit Bioscience, Techpool Bio-
Pharma, BioMarck Pharmaceuticals, Athersys, Apeptico Forschung und Entwicklung GmbH, Savara,
Cynata Therapeutics, and others are investing their time and money to advance the ARDS pipeline. The
ARDS emerging therapies such as Traumakine (Faron Pharmaceuticals) and BIO11006 (BioMarck
Pharmaceuticals) are going to singnificantly impact the ARDS market size in a positive manner, says
DelveInsight.